company background image
6955 logo

Shandong Boan Biotechnology SEHK:6955 Stock Report

Last Price

HK$10.18

Market Cap

HK$5.2b

7D

-9.6%

1Y

-50.0%

Updated

26 Mar, 2024

Data

Company Financials +

Shandong Boan Biotechnology Co., Ltd.

SEHK:6955 Stock Report

Market Cap: HK$5.2b

6955 Stock Overview

Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in the People’s Republic of China and internationally.

6955 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Shandong Boan Biotechnology Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shandong Boan Biotechnology
Historical stock prices
Current Share PriceHK$10.18
52 Week HighHK$24.20
52 Week LowHK$9.29
Beta0
1 Month Change-1.74%
3 Month Change-30.37%
1 Year Change-49.98%
3 Year Changen/a
5 Year Changen/a
Change since IPO-48.59%

Recent News & Updates

Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking

Mar 26
Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking

Recent updates

Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking

Mar 26
Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking

Shareholder Returns

6955HK BiotechsHK Market
7D-9.6%-5.5%-1.2%
1Y-50.0%-43.0%-12.2%

Return vs Industry: 6955 underperformed the Hong Kong Biotechs industry which returned -43% over the past year.

Return vs Market: 6955 underperformed the Hong Kong Market which returned -12.2% over the past year.

Price Volatility

Is 6955's price volatile compared to industry and market?
6955 volatility
6955 Average Weekly Movement9.1%
Biotechs Industry Average Movement9.9%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6955's share price has been volatile over the past 3 months.

Volatility Over Time: 6955's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013745Hua Jianghttps://www.boan-bio.com

Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in the People’s Republic of China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), advanced recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The company develops BA1102 denosumab injection to treat patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as GCTB; and LY-CovMab to treat COVID-19.

Shandong Boan Biotechnology Co., Ltd. Fundamentals Summary

How do Shandong Boan Biotechnology's earnings and revenue compare to its market cap?
6955 fundamental statistics
Market capHK$5.18b
Earnings (TTM)-HK$129.37m
Revenue (TTM)HK$669.88m

7.7x

P/S Ratio

-40.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6955 income statement (TTM)
RevenueCN¥618.13m
Cost of RevenueCN¥209.16m
Gross ProfitCN¥408.97m
Other ExpensesCN¥528.35m
Earnings-CN¥119.38m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.23
Gross Margin66.16%
Net Profit Margin-19.31%
Debt/Equity Ratio30.0%

How did 6955 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.